Objectives
Our study objective was to analyse adverse events in adolescent and adult Berlin Heart EXCOR patients and to assess outcome of subsequent heart transplantation (HTX)
Methods
From 2006 to 2020, 58 patients (12–64 years) received a biventricular assist device (BIVAD) at our institution and were included in this study.
Results
Causes of biventricular heart failure were non-ischaemic cardiomyopathy (62.1%), ischaemic cardiomyopathy (22.4%) and myocarditis (15.5%). Median INTERMACS score was I (I—III). Median age was 49 years (IQR 34–55 years) and 82.8% were male. Causes of death were: multi-organ failure (25.0%), septic shock (17.9%), cerebral haemorrhage (14.3%), bleeding (14.3%) and embolic events (14.3%). Major bleedings were more frequent in the group who died on BIVAD (60.7 vs 6.7%, p < 0.001). Wound infections were more prevalent in HTX recipients (n = 21, 70.0%). After BIVAD thrombosis, 104 chamber exchanges were performed in 28 patients (48.3%). HTX was performed in 52.6% of the patients after BIVAD support time 316 ± 240 days. Mean time to follow-up of 30 HTX recipients was 1722 ± 1368 days. One-, 6- and 12-month-survival after heart transplantation were 96.7%, 90.0% and 76.7% respectively. Long-term survival after 5 and 10 years was 69.7%.
Conclusions
Pump thrombosis, infections and bleeding after BIVAD did not preclude successful HTX. Although only 50% of BIVAD patients were successfully transplanted, long-term survival after HTX in BIVAD patients was non-inferior when compared to other recipients.